Chronic Scrotal Content Pain FAQs
What is chronic scrotal content pain (CSCP)?
Chronic scrotal content pain (CSCP) refers to bothersome pain localized to structures within the scrotum that has been present for ≥ 3 months. Etiologies include infection, trauma, and referred pain from the spine, abdomen, and retroperitoneum.
Who typically suffers from CSCP?
CSCP is a common entity afflicting men of all ages and has been reported to peak in the mid to late thirties.
What are the current standards of care for CSCP?
Effective treatment options for CSCP are limited. Conservative therapies include rest, ice and scrotal supports along with pain education and counselling. There is no standardized protocol for treatment, but the mainstay of medical therapy involves nonsteroidal anti-inflammatory drugs with tricyclic antidepressants or gabapentin as alternatives.
Non-invasive options include pelvic floor physiotherapy, acupuncture or transcutaneous electrical nerve stimulation. Lidocaine combined with steroid injections have proven to be of some relief for men with testicular pain.
Surgical management is reserved for those who have persistent scrotal pain despite adequate trials of conservative and medical therapies. In the past, surgery for scrotal pain has focused on the area of the scrotum thought to be the source of pain.
Overall, the treatment of CSCP is challenging due to its multifaceted etiology and indistinct presentation, which poses a significant burden on the patient and physician. Many patients with CSCP are left with untreated pain, seeking consultation with multiple physicians.
Where can I get more information about the Sustained Therapeutics CSCP clinical trial?
The ST-CP-202 clinical trial is being conducted in male patients that have been experiencing chronic scrotal pain for more than 3 months. The study is being conducted at 4 centers across Canada and is expected to enroll approximately 63 participants. The purpose of the study is to determine if repeat injections of ST-01 are safe and effective in reducing chronic scrotal pain as compared to a control group receiving standard of care lidocaine.
